Screening for Retinopathy Every Two Years Deemed Safe

Share this article:
Screening for Retinopathy Every Two Years Deemed Safe
Screening for Retinopathy Every Two Years Deemed Safe

(HealthDay News) – For patients with type 2 diabetes without evidence of retinopathy, increasing the screening interval to every two years yields no increased risk of retinopathy-mediated vision loss and reduces screening costs, according to a study published online May 7 in Diabetes Care.

Daniel Chalk, PhD, of the University of Exeter in the United Kingdom, and colleagues developed a model to simulate the progression of retinopathy in patients with type 2 diabetes to predict the potential rates of retinopathy-mediated vision loss which would accompany increasing the interval between retinal screening to two years. Fifteen-year forecasts were generated to assess the differences between the proposed and current screening policies.

Using the simulation model, the researchers predicted that increasing the screening interval for patients with type 2 diabetes with no evidence of retinopathy would not increase the risk of vision loss. The proposed two-year screening interval could reduce costs by approximately 25%.

"The predictions generated by the model certainly present an appealing argument for extending the screening interval for diabetic retinopathy in a subset of type 2 diabetes patients," the authors write. "Our predictions also support the findings of other studies that have found longer screening intervals for diabetic retinopathy to be cost-effective."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs